Cancer Survivorship

Darryl Leong

Scientist

Darryl Leong is a Scientist at PHRI, Director of the McMaster University and Hamilton Health Sciences Cardio-Oncology Program, Associate Professor, Department of Medicine (Cardiology), McMaster University, and Staff Cardiologist at Hamilton Health Sciences. He has methodological expertise in clinical epidemiology and clinical trials, and content expertise in physical frailty, echocardiography, and cardio-oncology. His research is supported by the CIHR, and he has published more than 100 manuscripts including all the leading internal medical and cardiovascular journals.

He graduated from the University of Adelaide Medical School with Deans Listing and Honours for academic excellence, completed his cardiology training, Doctor of Philosophy, Master of Public Health, and Master of Biostatistics degrees at the University of Adelaide in Australia, and completed a post-doctorate fellowship in cardiovascular imaging at the Leiden University Medical Centre in The Netherlands, before re-locating to Canada.

PJ Devereaux

Senior Scientist

PJ Devereaux is Senior Scientific Lead, Perioperative and Surgery, PHRI, Professor and University Scholar in the Departments of Health Research Methods, Evidence, and Impact (HEI) and Medicine at McMaster University, and Director of the Division of Cardiology at McMaster.

The focus of his clinic research is vascular complications around the time of surgery, leading several large, international RCTs and observational studies addressing this issue. He has published more than 250 peer-reviewed papers and more than 50 book chapters and editorials. He is supported by a Tier 1 Canadian Research Chair in Perioperative Medicine, and holds the Yusuf Chair in Cardiology at McMaster University.

David Conen

Scientist

David Conen is an investigator at PHRI, and Associate Professor, Medicine, McMaster University. A clinical cardiologist with training in performing echocardiography, David’s research involves the conduct of large epidemiological cohort studies to study risk factors for the occurrence of atrial fibrillation and its consequences. He is also interested in clinical trials on therapies to prevent atrial fibrillation and the complications associated with the arrhythmia.

He received numerous prestigious grants in Switzerland and is the Principal Investigator of a large national cohort study to assess the relationship between atrial fibrillation and cognitive decline (Swiss-AF). He also leads another large cohort study of young and healthy individuals (GAPP), with a key focus on assessing risk factors for the development of cardiovascular risk factors in the general population.

Deborah Siegal

Associate Scientist

Deborah Siegal is an Associate Professor in the Department of Medicine within the Division of Hematology at the University of Ottawa. Her primary research interests include (i) improving patient outcomes after anticoagulant-related bleeding, (ii) management of anticoagulants in patients who have acute bleeding complications or require urgent surgery, (iii) understanding the factors that influence patient and physician decision-making after anticoagulant-related bleeding, and (iv) reducing red blood cell transfusion by minimizing iatrogenic blood loss for laboratory testing.

With expertise in the design and conduct of pragmatic cluster randomized trials, individual patient randomized trials, mixed-methods studies, observational studies and meta-analyses, Dr. Siegal has received peer-reviewed grant support as principal investigator from the Canadian Institutes of Health Research, the American Society of Hematology, CanVECTOR/Heart and Stroke Foundation of Canada, Ontario AFP Innovation Fund, and Hamilton Health Sciences Foundation. She has published 70 peer-reviewed articles including several in high-impact journals such as The New England Journal of Medicine, Circulation, Blood, and Journal of Thrombosis and Haemostasis.

She graduated from Queen’s University School of Medicine in 2009 and completed Internal Medicine and Hematology training at McMaster University. She holds Master of Science degrees in Pharmacology (University of Toronto) and Health Research Methodology (McMaster University).

Sumathy Rangarajan

Program Director

Sumathy Rangarajan has been Program Director, Global Health, since 2016, preceded by many years’ service at PHRI in other roles. She oversees the PURE study team, as well as the INVICTUS rheumatic AF treatment trial, the CANPWR pediatric weight management registry, and others.

She holds both a Bachelor of Science Degree and a Master of Science degree from Pune University in India.